Millipore Sigma Vibrant Logo
Home>Events>A3P BioProduction International Congress
Visit us at booth #37

Meet our team at A3P BioProduction International Congress

June 27-28, 2018 in Geneva, Switzerland

Vibrant M MilliporeSigma

Visit us at Booth #37 to explore the future of bioprocessing together.

Next Generation Bioprocessing is considered to be any technology, expendable, or system which significantly changes the existing monoclonal antibody manufacturing template to deliver higher productivity, increased manufacturing flexibility, increased speed, and reduced risk.

Meet our experts to get insights and perspectives on the on-going paradigm shift and evolution towards Next Generation Bioprocessing occurring in today’s and tomorrow’s biopharmaceutical landscape.

Explore what's next at MilliporeSigma!

Visit the Event Website

Mercrobe MilliporeSigma

Mark your calendar! You don’t want to miss our expert speakers!

Wednesday, June 27th

10:00 - 10:30mAb purification process intensification: evaluation of a fully-connected DSP process operated in flow-through mode
 Nicolas Laroudie, Biomanufacturing Engineer, Manufacturing Sciences & Technology, EMEA, MilliporeSigma
 

The purpose of the actual study was to evaluate the coupling of three orthogonal technologies, used either in flow-through or in frontal mode and without any pH or conductivity adjustment, to intermediate purify and polish a mAb post-viral inactivation. Activated carbon, coupled with cationic Eshmuno® CPX and anionic Eshmuno® Q resins all set inline, generated promising results and significant improvements in terms time, cost and footprint reduction, as well as increased productivity.

 

Thursday, June 28th

9:00 - 9:30New approaches for upstream scale-up transfer
 Flavien Thuet, Innovation Team Leader, MilliporeSigma
 

A new USP scale up strategy will be highlighted during this presentation. For further upstream processes, a scale transfer involving a better understanding of our production equipment will be used. Oxygen mass transfer models have been created for all the bioreactors used at MilliporeSigma Biodevelopment (at both process development and production scales) in order to be able to maintain this parameter constant. First results obtained at 200L scale with this more rational and controlled scale up approach will be shared. To conclude, an improvement of CO2 stripping strategy will be discussed.

 

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the US and Canada.